MY103182A - Vaccines against acquired immune deficiency syndrome. - Google Patents
Vaccines against acquired immune deficiency syndrome.Info
- Publication number
- MY103182A MY103182A MYPI87002188A MYPI19872188A MY103182A MY 103182 A MY103182 A MY 103182A MY PI87002188 A MYPI87002188 A MY PI87002188A MY PI19872188 A MYPI19872188 A MY PI19872188A MY 103182 A MY103182 A MY 103182A
- Authority
- MY
- Malaysia
- Prior art keywords
- immune deficiency
- acquired immune
- deficiency syndrome
- lav
- vaccines
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010001513 AIDS related complex Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940031348 multivalent vaccine Drugs 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229960004854 viral vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77990985A | 1985-09-25 | 1985-09-25 | |
| US84298486A | 1986-03-27 | 1986-03-27 | |
| US90521786A | 1986-09-09 | 1986-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY103182A true MY103182A (en) | 1993-05-29 |
Family
ID=27419757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI87002188A MY103182A (en) | 1985-09-25 | 1987-09-29 | Vaccines against acquired immune deficiency syndrome. |
Country Status (22)
| Country | Link |
|---|---|
| CN (1) | CN1020752C (fr) |
| AT (1) | ATA256786A (fr) |
| CH (1) | CH676247A5 (fr) |
| DE (1) | DE3690508T1 (fr) |
| DK (1) | DK455486A (fr) |
| ES (2) | ES2002490A6 (fr) |
| FI (1) | FI863848A (fr) |
| FR (1) | FR2587720A2 (fr) |
| GB (1) | GB2181435B (fr) |
| GR (1) | GR862412B (fr) |
| HU (1) | HU205780B (fr) |
| IE (1) | IE59314B1 (fr) |
| IL (1) | IL80073A (fr) |
| IT (1) | IT1195829B (fr) |
| MY (1) | MY103182A (fr) |
| NL (1) | NL8602422A (fr) |
| NO (1) | NO863803L (fr) |
| NZ (1) | NZ217645A (fr) |
| PT (1) | PT83434B (fr) |
| SE (4) | SE8604007L (fr) |
| WO (1) | WO1987002038A1 (fr) |
| YU (1) | YU46753B (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0220234B1 (fr) * | 1985-04-08 | 1994-08-03 | Genetic Systems Corporation | EXPRESSION ET UTILISATION DIAGNOSTIQUE DE PEPTIDES CODES gag ET IMMUNOLOGIQUEMENT REACTIFS A DES ANTICORPS DU LAV |
| US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
| US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
| US4983387A (en) * | 1986-05-19 | 1991-01-08 | Viral Technologies Inc. | HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus |
| JPS63119428A (ja) * | 1986-09-19 | 1988-05-24 | オンコーゲン | エイズの処置のための養子免疫療法の方法 |
| IE872748L (en) * | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
| JPS63258575A (ja) * | 1986-12-15 | 1988-10-26 | レプリゲン コーポレーション | 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク |
| FR2610632B1 (fr) * | 1987-02-11 | 1990-12-21 | Pasteur Institut | Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida |
| DE3855947T2 (de) * | 1987-01-16 | 1997-12-11 | Pasteur Institut | Peptide mit den immunologischen Eigenschaften von HIV-2 |
| US5681713A (en) * | 1987-05-08 | 1997-10-28 | Smithkline Beecham Corporation | Expression of heterologous proteins in Drosophila cells |
| GB8714802D0 (en) * | 1987-06-24 | 1987-07-29 | Proteus Biotech Ltd | Synthetic polypeptides |
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| FR2620030B1 (fr) * | 1987-09-07 | 1990-03-23 | Transgene Sa | Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus |
| IL89118A0 (en) * | 1988-02-03 | 1989-08-15 | Microgenesys Inc | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 |
| US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
| DE68917520T2 (de) * | 1988-05-06 | 1995-01-05 | Ferropas Ag | Verfahren und Systeme zur Herstellung von HIV-Antigenen. |
| US5043262A (en) * | 1988-05-12 | 1991-08-27 | Dana Farber Cancer Institute | Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use |
| AP129A (en) * | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5614404A (en) * | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
| US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
| US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
| AU3775789A (en) * | 1988-06-10 | 1990-01-05 | Applied Biotechnology, Inc. | A method of evaluating recombinant vaccines against immunodeficiency virus |
| US5665577A (en) * | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| DE69031735T2 (de) * | 1989-04-18 | 1998-03-12 | Applied Biotechnology Inc | Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren |
| AU5848390A (en) * | 1989-06-01 | 1991-01-07 | Applied Biotechnology, Inc. | Self-assembled, defective, non-self-propagating viral particles |
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| FR2676068B1 (fr) * | 1991-05-02 | 1994-11-04 | Pasteur Institut | Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant. |
| US5840312A (en) * | 1991-05-02 | 1998-11-24 | Institut Pasteur | Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein |
| CA2120137C (fr) * | 1991-11-08 | 2004-05-04 | The Upjohn Company | Vaccins contre le virus de la leucemie feline |
| DE4405810A1 (de) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
| CA2212682A1 (fr) | 1995-02-10 | 1996-08-15 | Worcester Foundation For Experimental Biology, Inc. | Apport de composes exogenes |
| US6013506A (en) * | 1995-06-05 | 2000-01-11 | Wardley; Richard C. | Feline leukemia virus vaccines |
| DE59507617D1 (de) * | 1995-09-06 | 2000-02-17 | Schablonentechnik Kufstein Ag | Verfahren zum Herstellen einer Siebdruckschablone |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US6723558B1 (en) | 1996-01-23 | 2004-04-20 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| ATE508735T1 (de) | 2001-12-19 | 2011-05-15 | Novartis Ag | Pulmonale verabreichung von aminoglykosiden |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0127839B1 (fr) * | 1983-05-27 | 1992-07-15 | THE TEXAS A&M UNIVERSITY SYSTEM | Procédé pour la préparation d'un vecteur recombinant d'expression de baculovirus |
| US4662514A (en) * | 1983-11-01 | 1987-05-05 | Charleswater Products, Inc. | Electrically conductive polymeric tubes for static sensitive electronic devices |
| US9328391B1 (en) * | 1984-08-22 | 2016-05-03 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cloning and expression of HIV-1 DNA |
| IL76082A (en) * | 1984-08-22 | 1991-07-18 | Us Health | Molecular clones of the genome of htlv-iii and a process for the preparation thereof |
| GB8501473D0 (en) * | 1985-01-21 | 1985-02-20 | Pasteur Institut | Cloned dna sequences |
| ATE250083T1 (de) * | 1984-10-18 | 2003-10-15 | Pasteur Institut | Lav-antigene und -peptide |
| CA1341423C (fr) * | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Proteines recombinantes de virus associes au syndrome d'adenopathie et/ou au syndrome d'immuno-deficience acquise |
| ATE138100T1 (de) * | 1984-12-24 | 1996-06-15 | Genentech Inc | Fusionen von aids-verwandten polypeptiden |
| US4774175A (en) * | 1985-03-01 | 1988-09-27 | Centocor, Inc. | Immunochemical methods for the detection of antibody against HTLV-III |
| NZ215867A (en) * | 1985-04-19 | 1989-10-27 | Hoffmann La Roche | Aids envelope protein, dna vectors and method of production |
| FR2586427B1 (fr) * | 1985-08-20 | 1988-12-09 | Pasteur Institut | Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes |
-
1986
- 1986-09-22 NZ NZ217645A patent/NZ217645A/xx unknown
- 1986-09-22 GR GR862412A patent/GR862412B/el unknown
- 1986-09-23 SE SE8604007A patent/SE8604007L/xx not_active Application Discontinuation
- 1986-09-23 IE IE252586A patent/IE59314B1/en not_active IP Right Cessation
- 1986-09-24 GB GB8622987A patent/GB2181435B/en not_active Expired - Fee Related
- 1986-09-24 ES ES8602123A patent/ES2002490A6/es not_active Expired
- 1986-09-24 FI FI863848A patent/FI863848A/fi not_active IP Right Cessation
- 1986-09-24 HU HU864072A patent/HU205780B/hu not_active IP Right Cessation
- 1986-09-24 NO NO863803A patent/NO863803L/no unknown
- 1986-09-24 IT IT67730/86A patent/IT1195829B/it active
- 1986-09-24 DK DK455486A patent/DK455486A/da not_active Application Discontinuation
- 1986-09-24 CH CH3821/86A patent/CH676247A5/fr not_active IP Right Cessation
- 1986-09-25 WO PCT/US1986/002002 patent/WO1987002038A1/fr active Application Filing
- 1986-09-25 NL NL8602422A patent/NL8602422A/nl not_active Application Discontinuation
- 1986-09-25 AT AT0256786A patent/ATA256786A/de unknown
- 1986-09-25 CN CN86106632A patent/CN1020752C/zh not_active Expired - Fee Related
- 1986-09-25 YU YU165486A patent/YU46753B/sh unknown
- 1986-09-25 FR FR8613414A patent/FR2587720A2/fr active Granted
- 1986-09-25 PT PT83434A patent/PT83434B/pt not_active IP Right Cessation
- 1986-09-25 DE DE19863690508 patent/DE3690508T1/de not_active Withdrawn
- 1986-12-31 IL IL8007386A patent/IL80073A/en not_active IP Right Cessation
-
1987
- 1987-09-29 MY MYPI87002188A patent/MY103182A/en unknown
-
1988
- 1988-05-13 ES ES8801494A patent/ES2006941A6/es not_active Expired
-
1991
- 1991-10-14 SE SE9102976A patent/SE9102976L/xx not_active Application Discontinuation
- 1991-10-14 SE SE9102975A patent/SE9102975L/xx not_active Application Discontinuation
- 1991-10-14 SE SE9102974A patent/SE9102974L/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY103182A (en) | Vaccines against acquired immune deficiency syndrome. | |
| ES8801318A1 (es) | Un procedimiento para la produccion de un peptido. | |
| ATE258188T1 (de) | Retro-, inverso-, und retro-inverso synthetische peptidanaloge | |
| SE8701413D0 (sv) | Expression and purification of an htlv-iii gag/env gene protein | |
| DK0584348T3 (da) | Genetisk vaccine mod immundefektvirusser | |
| NZ219113A (en) | Hiv peptide containing epitope of the env protein | |
| WO1991004273A3 (fr) | Nouveaux peptides associes a la region de liaison cd4 de la gp120 et leur mode d'emploi | |
| EP0090581A3 (fr) | Petits peptides specifiques des antigènes de la fièvre aphteuse | |
| ATE105334T1 (de) | Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3. | |
| ES8404186A1 (es) | "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b". | |
| NO912825D0 (no) | Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper. | |
| DE69327529D1 (de) | Immunologisch mit HLA homologe HIV Protein Epitope | |
| ATE72400T1 (de) | Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen. | |
| NO175846C (no) | Fremgangsmåte for å oppnå et immunogen | |
| NZ220500A (en) | Recombinant felv polypeptide; vaccine and expression vectors | |
| DE69433057D1 (de) | Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus | |
| SE9202934D0 (sv) | Vacciner mot melanom | |
| ATE122236T1 (de) | Vorläufer des hüllenglykoproteins des hiv-2 retrovirus und verwandte antigene. |